Our studies have uncovered BRD4 as a key vulnerability in NRAS‐mutant melanoma and establish that co‐targeting BET and MEK may be an effective strategy that could be rapidly translated for the treatment of melanoma refractory to current therapies. Here, NRAS is linked to melanoma.